Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 15:8:657109.
doi: 10.3389/fmed.2021.657109. eCollection 2021.

Hepatitis B Virus Screening Before Cancer Chemotherapy in Taiwan: A Nationwide Population-Based Study

Wei-Chih Sun  1   2 , Pei-Ling Tang  3   4   5 , Wen-Chi Chen  1   2 , Feng-Woei Tsay  1   2 , Huay-Min Wang  1   2 , Tzung-Jiun Tsai  1   2 , Sung-Shuo Kao  1   2 , Jin-Shiung Cheng  1   2 , Wei-Lun Tsai  1   2   6
Affiliations

Hepatitis B Virus Screening Before Cancer Chemotherapy in Taiwan: A Nationwide Population-Based Study

Wei-Chih Sun et al. Front Med (Lausanne). .

Abstract

Background: Reactivation of the hepatitis B virus (HBV) during cancer chemotherapy is a severe and sometimes fatal complication. In 2009, the National Health Insurance (NHI) in Taiwan recommended and reimbursed screening for HBV infection and prophylactic antiviral therapy before cancer chemotherapy. In this study, we determined the HBV screening rate in patients with cancer undergoing chemotherapy in Taiwan. Methods: We retrospectively collected data from the National Health Insurance Research Database on patients who received systemic chemotherapy for solid or hematologic cancers from January 2000 through December 2012. We defined HBV screening based on testing for serum HBsAg within 2 years of the first chemotherapy commencement. We calculated overall and annual HBV screening rates in all patients and subgroups of age, gender, cancer type, hospital level, physician's department, and implementation of NHI reimbursement for HBV screening before cancer chemotherapy. Results: We enrolled 379,639 patients. The overall HBV screening rate was 45.9%. The screening rates were higher in males, those with hematological cancer, those at non-medical centers and medical departments. The HBV screening rates before (2000-2008) and after the implementation of NHI reimbursement (2009-2012) were 38.1 and 57.5%, respectively (p < 0.0001). The most common practice pattern of HBV screening was only HBsAg (64.6%) followed by HBsAg/HBsAb (22.1%), and HBsAg/HBcAb/HBsAb (0.7%) (p < 0.0001). The annual HBV screening rate increased from 31.5 to 66.3% (p < 0.0001). The screening rates of solid and hematological cancers significantly increased by year; however, the trend was greater in solid cancer than in hematological cancer (35.9 and 26.2%, p < 0.0001). Conclusions: The HBV screening rate before cancer chemotherapy was fair but increased over time. These figures improved after implementing a government-based strategy; however, a mandatory hospital-based strategy might improve awareness of HBV screening and starting prophylactic antiviral therapy before cancer chemotherapy.

Keywords: HBV screening; cancer; chemotherapy; hepatitis; hepatitis B virus.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Changes in the annual HBV screening rate.
Figure 2
Figure 2
Changes in the annual HBV screening rate in solid and hematological cancers.
See this image and copyright information in PMC

References

    1. World Health Organization . Hepatitis B. Fact Sheet 204. Available online at: http://www.who.int/mediacentre/factsheets/fs204/en/ (accessed January 8, 2018).
    1. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. (2015) 61:703–11. 10.1002/hep.27609 - DOI - PMC - PubMed
    1. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. (2017) 152:1297–309. 10.1053/j.gastro.2017.02.009 - DOI - PMC - PubMed
    1. Liu Z, Jiang L, Liang G, Song E, Jiang W, Zheng Y, et al. . Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: a review and meta-analysis of prophylaxis management. J Viral Hepat. (2017) 24:561–72. 10.1111/jvh.12672 - DOI - PubMed
    1. Voican CS, Mir O, Loulergue P, Dhooge M, Brezault C, Dréanic J, et al. . Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Ann Oncol. (2016) 27:2172–84. 10.1093/annonc/mdw414 - DOI - PubMed

LinkOut - more resources